John Alam

Also affiliated with Concello de Cervo, Vifor Pharma (United States)

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Disease-modifying pharmacological approaches to correcting basal forebrain cholinergic neuronal (BFCN) dysfunction and degeneration”.

Disease-modifying pharmacological approaches to correcting basal forebrain cholinergic neuronal (BFCN) dysfunction and degeneration

Neuropsychopharmacology(2021)10.1038/s41386-021-01135-x

N/A

0DataRank · unranked

2 citations

Ralph A. Nixon, John Alam

Correction: Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come

Molecular Neurodegeneration(2023)10.1186/s13024-023-00678-5

N/A

0DataRank · unranked

0 citations

Ralph A. Nixon, John Alam

Perspective: Minimally clinically important “symptomatic” benefit associated with disease modification resulting from anti‐amyloid immunotherapy

Alzheimer s & Dementia Translational Research & Clinical Interventions(2025)10.1002/trc2.70035

N/A

0DataRank · unranked

2 citations

Marwan N. Sabbagh, John Alam